HKSTP
13.1.2021 12:32:31 CET | Business Wire | Press release
Organised by the Innovation and Technology Commission together with the Hong Kong Science and Technology Parks Corporation, the first City I&T Grand Challenge was launched. In light of the new normal under the epidemic, the theme of the competition this year is “Innovating for Hong Kong’s New Normal” and invites all sectors of the community to put forward innovation and technology (I&T) solutions focusing on two issues, namely environmental sustainability and social connectivity, to tackle problems facing the city and people in their daily lives. A series of workshops and other activities will also be held to create an I&T atmosphere in the whole community.
In his video speech for the launch of the event, the Financial Secretary, Mr Paul Chan, said that the Government has allocated over $100 billion in recent years for I&T infrastructure and development. It has provided full support for nurturing I&T talents and fostering an I&T ecosystem. It is committed to improving the entire I&T industry chain from research and development (R&D) to production and marketing, enabling local I&T talents and enterprises to excel. The COVID-19 epidemic has led people to change their old lifestyles and to think about how to solve problems with technology. He believes that the City I&T Grand Challenge will draw creative ideas from all sectors for developing I&T and smart living proposals to help people live as usual and even in a better way in the new normal during and after the epidemic.
The Secretary for Innovation and Technology, Mr Alfred Sit, said in his video address that, in addition to promoting a diversified economy and injecting new impetus into the economy of Hong Kong, an even more important objective for the Government to push forward I&T development is to improve the quality of life, bringing convenience and benefits to members of the public. Describing the City I&T Grand Challenge as an “I&T marathon”, Mr Sit hoped the whole community could take part in and benefit from it. He also hoped that the City I&T Grand Challenge will fuel community-wide enthusiasm for I&T, especially among young people.
Speaking at the media briefing of the competition, the Commissioner for Innovation and Technology, Ms Rebecca Pun, said that, while some business plan competitions put focus on the team members and product development capabilities of a company and its investment prospects, the City I&T Grand Challenge evaluates each proposal based on its originality, uniqueness and effectiveness, application of innovation and technology, as well as social benefits and impact.
Also speaking at the briefing, the Chief Executive Officer of the Hong Kong Science and Technology Parks Corporation, Mr Albert Wong, said that everyone has the potential to be an innovator to shape the future. The City I&T Grand Challenge offers an invaluable opportunity for the public to apply creativity and develop smart solutions catering to the new normal under the epidemic for the benefit of the community.
The City I&T Grand Challenge is open for application from today till 24 April 2021. Target participants range from primary and secondary school students to local and non-local tertiary students, technology enterprises, R&D teams and entrepreneurs. Winners will be awarded a cash prize and a trophy. For the winners of the University and Open categories, they will also have a chance to receive R&D resources and training for refining their I&T solutions for trying at a designated venue such as a government department or a public organisation.
Under each of the focused issues of environmental sustainability and social connectivity, the City I&T Grand Challenge sets up two specific scenarios for participants to select for developing innovative solutions. For “environmental sustainability”, the two scenarios are surrounding disposable plastic tableware and household food waste, which are pressing environmental problems in the new normal. As regards “social connectivity”, the two scenarios are mainly concerned about the physical and social well-being of senior citizens and children under the new normal of social distancing and distant learning.
The website of the City I&T Grand Challenge has been launched for the public to submit applications. A host of workshops, seminars and training activities will also be organised to introduce knowledge on technologies and entrepreneurship as well as topical daily life issues. All are welcome to join. Details are available at the event website (citytechgc.hk ).
*Videos and images are available for download here .
About Hong Kong Science and Technology Parks Corporation
Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.
Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.
Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long. More information about HKSTP is available at www.hkstp.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom